Welcome to the EF-CLIF web-page, the main working tool of our investigators. All protocols of the multicenter prospective observational studies and randomized controlled trials performed by our network of Hospitals and their clinical research forms are loaded in the reserved research area of the webpage. You will find in other areas detailed information related to the organization, rules, steering committees, research facilities and scientific production as well as the past and the future educational activities of the EF CLIF.
The last member to join the project has been Instituto de Salud Digestiva y HepŠtica in Guadalajara (Mexico) in June '18.READ MORE
Dr Wenji Gu is a medical investigator, currently finishing her Master at the Department of Gastroenterology in Ren Ji Hospital, School of Medicine, and at Key Laboratory of Gastroenterology & Hepatology in Shanghai Jiao Tong University.READ MORE
The change is aimed to prepare the Foundation to major challenges coming in the near future, including a significant increase in the number of projects and funds, the participation of the Foundation in EU grants and the incorporation of high throughput omics technology in most observational studies and projects.READ MORE
More than 80 investigators of the EASL Clif Consortium took part in the Assembly where the speakers gave a comprehensive overview of the latest researches in the setting of EF Clif and had the opportunity to exchange experiences.READ MORE
Among the participants, there were most Steering Committee Members of the EASL-CLIF Consortium, a selected group of investigators from the PREDICT Study, the Principal Investigators of the 2018 research program of the EF Clif, members of the Grifols Chair, Dr Tom Henning Karlsen, EASL General Secretary, Professors Roger Williams and Flair CarrilhoREAD MORE
The CANONIC study has shown that among patients with acute decompensation (AD) of cirrhosis, those who had Acute-on-Chronic Liver Failure (ACLF, characterized by intense systemic inflammation, organ failures and poor outcome) were clearly distinct from those with traditional AD (who do not have organ failures and have good outcome).READ MORE